INTRODUCTION
Individual randomized trials of interventional strategies in non ST elevation acute coronary syndrome (ACS) have reported short [1] [2] [3] [4] [5] [6] [7] or longer-term outcomes [8] [9] [10] , but with differing conclusions. Uncertainty remains regarding the long-term benefits versus hazards of a routine early invasive strategy (angiography followed by revascularization where clinically indicated), and whether the outcomes are dependent on the baseline risk of patients [11] [12] [13] [14] [15] . Whereas early results of some trials (FRISC II, RITA-3, TACTICS-TIMI 18) showed benefits [4] [5] [6] , especially in reduced rates of myocardial infarction (MI) and refractory angina, there was no evidence of benefit in the ICTUS trial 7 . Moreover, longer-term mortality and cardiovascular (CV) mortality results of the individual trials appear inconsistent and either showed no benefit, or trends at the margins of statistical significance [8] [9] [10] illustrating a lack of statistical power for any one trial to reach definitive conclusions. Previous pooled analyses have not been conducted using individual patient data and outcome data beyond one year were not included [14] [15] [16] . Differences in outcomes in the respective trials may be the result of differences in inclusion criteria, in baseline characteristics of the patients, differences in the timing and threshold for revascularization, differences in adjunctive therapies, and other factors including the play of chance. An overall long-term meta-analysis is therefore required to define more reliably the relative risks and benefits of routine invasive and conservative strategies, particularly for CV mortality and non-fatal MI. Such an analysis would have substantially greater power to determine the impact on mortality and to explore how the effects depend on patients' baseline risk.
The FIR collaboration involves the three randomized trials with long-term outcome data (5 year outcome) and was established in order to conduct a meta-analysis based upon individual patient data. Specifically, the aim of the meta-analysis was to determine whether a routine invasive strategy is beneficial compared to a conservative (selective invasive) strategy in the overall population of patients with non ST elevation ACS, and to allow a reliable estimate of the net impact of an interventional strategy despite the differences from trial to trial. The secondary aim was to determine whether the relative or absolute difference in between the treatment strategies differed according to the baseline risk of the patients. Resolving these issues has the potential to influence triage decisions for the spectrum of patients presenting with non-ST elevation ACS and guidelines suggest the importance of risk stratification 11, 12, 13 .
METHODS

Study population and procedures
A computerized literature search was conducted from 1970 to 2009 of the MEDLINE and Cochrane databases by using terms that included invasive strategy, conservative strategy, selective invasive strategy, intervention, acute coronary syndromes, non-ST elevation myocardial infarction, and unstable angina. Three 47 randomized trials with long-term outcomes were identified, that met these criteria (FRISC II, RITA-3, and ICTUS) [8] [9] [10] . TACTICS-TIMI 18 has only 6 month outcome data 5 and none of the smaller trials has 5 year outcomes published or presented [1] [2] [3] [14] [15] [16] . Individual outcomes and the design of the FRISC II, RITA-3, and ICTUS trials have been reported previously [8] [9] [10] . The previous publication of RITA-3 reported outcomes at a median of five years and for consistency across the trials the results are now extended with complete five year follow-up for all patients.
These trials compared a routine invasive strategy with a selective invasive strategy in patients with non ST elevation ACS but with differing criteria for the eligible population. The routine invasive strategy consisted of "early" coronary angiography and the timing of this reflected current clinical practice (within 24-48 hours of randomization in ICTUS, within 72 hours in RITA-3 and within 7 days in FRISC II). The decision to proceed to percutaneous or surgical revascularization was based on the angiographic findings. The threshold for proceeding to intervention differed in both the selective and in the routine invasive strategies in the three trials. Coronary artery bypass grafting (CABG) was recommended with severe left main stem or three-vessel disease, yet the frequency of CABG differed in the three trials. In each trial the selective invasive "conservative" strategy consisted of initial medical treatment with coronary angiography and revascularization only for refractory or an accelerating pattern of angina despite optimal medical treatment (or in the case of haemodynamic or rhythmic instability in ICTUS). In the FRISC II and ICTUS trials, a pre-discharge ischemia detection test was systematically performed, with criteria for "crossing over" to intervention from the selective invasive strategy 4, 7, [9] [10] . By design, in RITA-3 the indication for coronary arteriography in the selective invasive strategy was symptom driven 6, 8 .
Setting and data collection
The principal investigators of FRISC II, RITA-3 and ICTUS (LW, KAAF, RJdW) initiated this collaborative analysis, and a protocol was written summarizing the main pre-specified analyses and a common set of baseline and outcome variables. Investigators from the three trials provided individual patient data to form a pooled patient database in accordance with previously published methodologies 1-3, 5, 13-16 . The database included core variables on demographics, clinical history, risk factors for coronary artery disease, baseline electrocardiographic characteristics, biomarkers of myocardial necrosis and 5-year clinical outcomes. Data-sets from each trial were sent for merging to the coordinating Academic Medical Center in Amsterdam, the Netherlands. The merged database was checked for completeness and consistency by all three participating sites.
Outcomes
The primary outcome was the composite of CV death or non-fatal MI. Other secondary outcomes included all-cause death, and non-fatal MI alone. Myocardial infarction was defined as pre-specified in each trial: MI in the FRISC II trial was defined by the occurrence of 2 of the following conventional criteria; typical chest 3 FIR 5-YEAR OUTCOMES pain, diagnostic electrocardiographic recording (new Q waves), and elevation in one cardiac biomarker above the upper limit of normal (ULN) with spontaneous MIs, or elevation in one cardiac biomarker up to 1.5 the ULN with procedurerelated MIs 4 . MI in the RITA-3 trial was defined as diagnostic electrocardiographic recoding (new Q waves) or by the combination of a typical clinical event, electrocardiographic evidence of acute infarction and an elevation in one cardiac biomarker up to twice the ULN 6 . MI in the ICTUS trial was defined as myocardial necrosis in the setting of myocardial ischemia. Myocardial necrosis was defined as an elevation in one cardiac biomarker above the ULN with spontaneous MIs, or three times the ULN in case of a procedure-related MI 10 .
Statistical analysis
The main outcomes were tabulated by treatment group for each study, and overall, with 5-year cumulative event rates estimated with the Kaplan-Meier method. The impact of the intervention was assessed using Cox regression models, stratified by trial. For the primary outcome of CV death or non-fatal MI heterogeneity between treatment strategy and study was assessed using an interaction test in the Cox model. However, a model with trial entered as dummy variables was performed to assess whether this materially altered the hazard ratios for each predictor included. The coefficients in the final Cox model were rounded to produce an integer risk score to predict a patient's 5-year probability of CV death or MI. For each risk factor a score of zero is assigned to the lowest risk category and an individual's score increases by an integer amount for each level above the lowest category. In order to assess the effect of intervention according to risk, the integer score was calculated assuming the patient received the selective invasive strategy. Patients were then categorized into three risk groups (each of the three groups contained approximately a third of the primary outcome events). The percentage of patients with the primary outcome was tabulated by treatment group and risk category, along with hazard ratios and absolute risk differences, to consider whether the impact of intervention depended on underlying risk.
Risk categories were also defined based on the exact coefficients from the model to compare the results with those using the simple integer score. Finally, risk categorizations were used to assess the impact of intervention on CV mortality, and for all-cause mortality. All analyses were carried out using Stata version 10.1.
Funding support
The collaboration and the meta-analysis were conducted using resources from the host institutions for the respective studies (KAAF supported by the British 49 Heart Foundation; LW supported by the Swedish Heart Foundation) and from the London School of Hygiene and Tropical Medicine. The original studies were supported as stated in the original reports 4, 6, 7 .
RESULTS
Characteristics of the patients
Three randomized trials had outcome information with a minimum of 5 years of follow-up and the data were censored at 5 years. Overall, 2746 patients were assigned a selective invasive ("conservative") strategy and 2721 patients a routine invasive strategy. The mean age was 63.3 years, body mass index was 27.2kg/m 2 and 68.0% of the population were male. 24.2% of patients had a prior history of myocardial infarction and 5.7% had prior percutaneous coronary intervention (PCI). Prior CABG was uncommon (0.4% in FRISC II, excluded in RITA-3 and 8.8% in ICTUS). Approximately a third were current cigarette smokers at presentation, a third had prior documented hypertension and almost a quarter documented prior hypercholesterolaem.
Comparing the baseline characteristics across the three trials the majority of the patient demographics, the key risk factors, and the extent of prior coronary artery disease were very similar (table 1). Almost half of the patients (47.3%) had ST-segment deviation at presentation. There were some differences in baseline characteristics in respective trials including a higher proportion of patients presented with ST-segment depression on the admission ECG in FRISC II (47.1%) and ICTUS (44.6%) than in RITA-3 (36.5%) (table 1) . Troponin values were not available at baseline in all patients in RITA-3.
Revascularisation rates over time
Among those randomized to a routine invasive strategy approximately two-thirds (64.1%) underwent revascularization during the index hospitalisation, this figure rising to 71.8% at the end of one year and 73.3% at the end of three years. In comparison the rate of revascularization in hospital in those randomized to a selective invasive strategy was 17.6% but this rose to 41.6% at the end of one year and 47.8% at the end of three years (Kaplan Meier plot, figure 1 ). By design the individual trials allowed for angiography and revascularization on the basis of symptoms and objective signs of ischemia 4, 6, 7 and routine pre-discharge stress testing led to higher crossover rates to intervention in the selective invasive strategy patients, particularly in ICTUS 7, 10 . The Kaplan-Meier plot of revascularisation over time shows that most of those crossing to intervention from the selective invasive strategy had revascularisation performed within 3 months of presentation (figure 1).
Impact of the randomised treatment: overall clinical outcomes
Over the course of five years 14.7% (389 / 2721) of patients randomized to a routine invasive strategy experienced CV death or non-fatal MI compared with 17.9% (475 / 2746) randomized to the selective invasive strategy (hazard ratio figure 2 ). The confidence bounds were unaffected by adjustment for study (figure 2). Including all peri-procedure infarctions (table 2) the data for FRISC II and RITA 3 are unchanged and for ICTUS there were 14 additional patients with MIs with selective invasive but 38 additional patients with MIs for routine invasive. In consequence, combined, there were 487 (18.3%) CV deaths or MIs with selective invasive and 420 (15.9%) with routine invasive: HR 0.86 95% CI 0.76 to 0.98, p= 0.028. Considering deaths from any cause or non-fatal MIs, the findings were similar with a 15% hazard reduction for There were numerically fewer CV deaths among those randomized to a routine invasive strategy, (6.8%), versus those randomized to a selective invasive strategy, (8.1%) (HR 0.83 95% CI 0.68 to 1.01 p=0.068) (table 2). Deaths from any cause were also numerically fewer among those randomized to a routine invasive strategy (10.6% versus 11.7% in the selective invasive strategy, p=0.19) though this difference is not statistically significant (table 2) .
Comparing the outcomes across the trials the hazard ratios for the composite of CV death or non-fatal MI demonstrated similar findings in FRISC II (HR 0.79 95% CI 0.66 to 0.95) and RITA-3 (HR 0.75 95% CI 0.58 to 0.96) and in both studies the confidence bounds did not overlap unity (figure 2). In ICTUS the confidence bounds overlapped with those of the other two studies and with unity (HR 0.99 95% CI 0.72 to 1.35) (figure 2). There is no evidence of heterogeneity between trials (interaction p=0.37). The Kaplan-Meier plots for CV death or non-fatal MI demonstrate early separation of the curves in favor of the routine invasive strategy with sustained separation, and slight divergence over the course of the 5 years of follow-up (figure 3).
Multivariable predictors for CV death or MI at 5 years of follow-up
The univariable and multivariable predictors of CV death or non-fatal MI were derived (tables 3,4). The independent multivariable predictors for CV death or MI in the entire dataset were randomised treatment (HR 0.76, 95% CI, 0.67 to 0.87, p< 0.0001), age per 5 year interval, diabetes, prior MI, presentation with ST depression, hypertension, and low or elevated BMI (table 4).
The relation between baseline risk and outcome at 5 years of follow-up
In the high risk routine invasive group there were 130/423 CV deaths or non fatal MIs (32.1%) versus selective invasive group 159/379 (43.8%) HR 0.66 95% CI 0.52 to 0.83, risk difference -11.7%. In the moderate risk patients (29% of the cohort) the respective figures for the RI group were 134/791 (17.4%) versus SI 152/774 (20.3%) HR 0.86 (0.68 to 1.08), risk difference -2.9%. In the low risk patients (56% of the cohort) the respective figures for the RI group were 125/1507 (8.5%) versus SI 164/1593 (10.6%) HR 0.80 (0.63 to 1.01), risk difference -2.1%. The above risk differences are based on the exact coefficients: these agree closely with the simplified integer score.
In order to make the multivariable risk prediction more accessible to clinicians, it was converted into an integer score (table 5, figure 4). The simple integer scoring system is based on the multivariable predictors: age (up to 5 units), diabetes (4 units), previous MI (3 units), ST depression on presenting ECG (2 units), BMI (up to 2 units) and prior hypertension (1 unit). We formed three risk groups: low, moderate and high risk for integer scores of 0-4, 5-8 and ≥ 9 respectively. The aim was to have roughly equal numbers of primary outcomes in each risk group. As a consequence there are substantially more patients in the low risk group and fewer in the high risk group, compared with the moderate risk group (table 5) . The risk stratification demonstrated separation of outcome according to the categories of risk: for both strategies combined the rate of CV death or non-fatal MI was 9.3% in the low risk group (263/2926), 19.2% in the moderate risk group (341/1832), and 38.2% in the high risk group (260/709). As there was no significant heterogeneity in the relative effect on outcome over the risk groups the absolute impact of intervention differed in relation to the category of baseline risk (table 5, figure 5 ). The largest absolute reduction in CV death or MI was seen in the 13% of patients in the highest risk group (HR 0.68 95% CI 0.53 to 0.86, risk difference -11.1% 95% CI -18.4% to -3.8%). The 
Cardiovascular and all-cause mortality and risk group
There was a lower rate of CV mortality in the high risk routine invasive group (82/378 routine invasive, 84/331 selective invasive HR 0.83 95% CI 0.61 to 1.12, risk difference -3.8% 95% CI -10.3% to 2.7%) The high risk routine invasive group also showed a lower rate of all cause mortality (107/378 routine invasive, 107/331 selective invasive HR 0.84 95% CI 0.65 to 1.10, risk difference -4.0% 95% CI -10.9% to 2.8%). There were smaller but consistent absolute reductions even in the in the low risk group for both CV mortality (-1.1% 95% CI -2.3% to 0.1%) and all-cause mortality (-0.9% 95% CI -2.5% to 0.7%).
Thus the largest absolute difference in CV death or MI, and in all cause and CV mortality, was seen in the highest risk group. The test for interaction between treatment and risk score for CV death or MI was non significant on the hazard ratio scale (p=0.10) whereas it was highly significant on the risk difference scale (p<0.0001) and hence the results are consistent with more modest treatment effects (in terms of absolute differences) in lower risk groups. 
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DISCUSSION
Previous combined analyses have not been conducted using individual patient data and they lack outcomes beyond a year [14] [15] [16] . The hypothesis has been proposed that the timing of revascularization influences outcome but the most recent and largest of the studies 17 of timing did not demonstrate overall benefit of an early routine intervention compared with a delayed routine intervention [17] [18] [19] [20] . This meta-analysis, based on individual patient data of the three trials that assessed the long-term impact of a routine invasive strategy demonstrated a sustained advantage for the routine invasive strategy in reducing subsequent CV death or non fatal MI. The 19% relative risk reduction (HR 0.81, 95%CI 0.71 to 0.93) reflected a 3.2% absolute reduction in the combined endpoint. The difference was mainly driven by the 23% relative 2.9% absolute reduction in myocardial infarction. However, there was also a consistent strong trend to a reduction in cardiovascular and total mortality. The randomized treatment was applied on top of the contemporary standard of secondary prevention therapy and the treatment effect was seen despite the fact that adjunctive therapy and instrumentation evolved over the course of the successive trials (eg use of thienopyridines, glycoprotein IIb/IIIa antagonists, stent and catheter technology). Furthermore the benefit was seen despite a substantial cross-over to invasive treatment event in the non-invasive treatment arm in several of the trials.
Resolving the differences in outcome among the studies
The individual trials differed in their reported late outcomes. In FRISC II there were significant advantages for a routine invasive strategy at one, two and five years 9 . In RITA-3 there was no significant difference in CV death or MI at 1year but there was a significant difference at 5 years 6, 8 . At neither time point was there any significant difference in ICTUS 7, 10 . What accounts for the trial to trial differences? Firstly trial design: There were different inclusion criteria in the trials with more unselected populations included in first performed FRISC II and RITA-3 trials. The design of the ICTUS trial was informed by the risk indicators from the earlier trials including the FRISC II and TACTICS-TIMI 18 trials. In the ICTUS study, the patients were included were all troponin positive, and in addition had either ischemic chest pain or documented coronary artery disease. This may in part explain, at least in part, the high revascularization rate in the selective invasive arm of ICTUS. In FRISC II and RITA-3 there was a wide separation in the frequency of early and late revascularization rates between the two arms of the respective trials (FRISC II 71% within 10 days, 78% within 12 months in routine invasive group. This compares with 9% and 43% respectively in the in selective invasive group). In RITA-3: routine invasive group 44% within index hospitalization and 57% within 12 months compared with 10% and 28% respectively in the selective invasive group. In ICTUS: routine invasive group 76% within index hospitalization and 79% within 12 months compared with 40% and 54% respectively in the selective invasive group. Thus, especially the early rate of revascularization in the selective invasive 3 FIR 5-YEAR OUTCOMES strategy was substantially higher in ICTUS than in FRISCII or RITA-3, and the rate remained higher thereafter. In RITA-3 the rates of both early and late intervention, in the selective and routine invasive strategies were lower than in FRISCII and ICTUS -in fact the rate of intervention in the selective invasive arm of ICTUS resembled the rate in the routine invasive arm of RITA-3.
Do the outcomes differ according to the extent of baseline cardiovascular risk?
To resolve this issue univariable (table 3) and multivariable predictors (table 4) of CV death or MI were derived and the entire population was separated into three groups based on an integer score so that each risk group contained approximately a third of the outcome events. The identified risk characteristics and the results in the different risk groups correspond well to previous reports from the FRISC II trial 9, 23 . The most pronounced treatment effect was seen in the high risk group. However, although the treatment effect was less pronounced in the majority of patients at lower risk, the absolute number of events prevented was greater (20 events in the high risk group, 31 in the intermediate risk and 35 events in the low risk patients (table 5) . Interestingly, the Kaplan Meier plot suggests that the early invasive strategy is associated with a progressive benefit over time that may reflect a long-term reduced rate of MI because of avoidance of risk of episodes of ischemia and avoidance of the consequences of earlier myocardial injury on subsequent arrhythmic events and heart failure (increasing risk of CV mortality).
The relative and absolute benefits in the moderate and lower risk groups are of similar magnitude to those aimed for and seen in the overall results of recent trials of pharmaceutical treatments for non-STE-ACS (TRITON 21 , PLATO 22 ). However, the health economic considerations of smaller number needed to treat per patient saved in the higher risk subgroup but greater number of patients saved by treating also lower risk populations need greater attention when interpreting how trial findings are best applied to future patients 24 . In contrast to these findings from randomized trials, studies of clinical practice in multiple countries demonstrate a "treatment -risk paradox", whereby most interventions are performed in lower risk patients [22] [23] .
Can this risk model be converted into a readily usable integer risk predictor?
The simplified integer score demonstrates very similar separation of the risk groups and similar risk differences compared to the exact coefficients from the model used to determine risk. This integer score has the potential to be applied at the bedside, and without the need for a nomogram or calculator.
Strengths and limitations
This is the first meta-analysis of the long-term impact of a routine invasive strategy, on top of the current standard of adjunctive therapy. It is based on individual patient data.
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Add to score Age (years) <60 0 Rates of adjunctive therapy increased in each successive study and rates were highest in ICTUS. Rates of intervention were also highest in ICTUS (see discussion above). There were differences in the definition of MI by study and differences in the sensitivity for detection of MI. Detection of the early occurrence of re-MI presents diagnostic challenges in all studies of non ST elevation ACS. However, such differences in definition and diagnostic threshold of biomarkers would tend to add "noise" to the meta-analysis and diminish the probability of showing any real impact on CV death or MI. The sensitivity for detection of infarction, including peri-procedure infarction increased with successive studies and ICTUS routinely measured serial blood samples in patients for post PCI elevations of CK-MB mass . However, in ICTUS there was acknowledgement that peri-procedure infarctions were more readily detected during the initial in-hospital phase (in the routine invasive group) than in the selective invasive group (undertaken later) 10 . Specifically, of the 82 patients with MI in the routine invasive group, 35 (42.7%) had procedure-related MIs alone compared to 14/68 (20.5%) in the selective invasive group. Nevertheless, even including all these procedure related MIs in the meta-analysis, the routine invasive strategy has a reduced rate of CV death or non-fatal MI (hazard ratio 0.86 95% CI 0.76 to 0.98, p=0.028).
60-64 +1
65-69 +2
70-74 +3
≥75 +5
Diabetes
The use and sensitivity of biomarkers of necrosis evolved over the successive studies. As differing troponin assays were used and not all patients had troponin values, this variable was not included in the multivariable risk calculation. Nevertheless, based on the other independent predictors, patients could be separated clearly into the three categories of risk ( figure 5) .
Finally, the differences may be influenced by sample size and the play of chance (ICTUS was the smallest study and had limited power to resolve differences in death or MI). Nevertheless, as illustrated in figure 2 , the confidence intervals for outcomes overlap and despite the differences in design, the meta-analysis strongly suggests a benefit for the routine invasive strategy, even five years after randomization. This is despite subsequent late revascularizations in the selective strategy in each study, on account of symptoms and signs of ischemia.
Implications
Despite differences in trial design and in the evolution of adjunctive therapies and technologies, and individual differences from trial to trial in outcomes, the overall meta-analysis at 5 years shows a sustained reduction in the rate of CV death or MI by using a routine invasive strategy in patients with non-ST elevation ACS. The largest absolute benefit is observed in patients with higher baseline risk and such patients can be identified using simple clinical risk characteristics. However, even in intermediate and lower risk populations the benefits of an early invasive strategy are of similar magnitude as those aimed for and seen with current pharmacological interventions. It is remarkable that despite the systemic and diffuse nature of atheromatous disease, and disease progression elsewhere in the vascular system, an early routine revascularization strategy has a treatment benefit that is clearly evident after 5 years.
